3rd Annual Microbiome: Regulatory, Quality Developments and Commercialization Summit
16-17

October 2019

Germany

Berlin

Leonardo Royal Hotel Berlin Alexanderplatz

Otto-Braun-Straße 90, 10249

About

We are pleased to invite you to the 3rd Annual Microbiome: Regulatory, Quality Developments and Commercialization Summit scheduled for October 16-17, 2019, in Berlin, Germany. This premier B2B event provides you with an appropriate platform to engage with and discuss ideas with your fellow peers while facilitating a professional atmosphere and environment for excellent company representation and development. The Summit will shed light on current challenges, best practices and inside views of the future of microbiome-based products in relation t...

We are pleased to invite you to the 3rd Annual Microbiome: Regulatory, Quality Developments and Commercialization Summit scheduled for October 16-17, 2019, in Berlin, Germany. This premier B2B event provides you with an appropriate platform to engage with and discuss ideas with your fellow peers while facilitating a professional atmosphere and environment for excellent company representation and development. The Summit will shed light on current challenges, best practices and inside views of the future of microbiome-based products in relation to quality, safety and efficiency. We will discuss key findings, critical insights and recommendations for driving efficient strategies within the microbiome landscape. It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Berlin in October!

more info
Who Should Attend

Chief Executives, Directors, Vice Presidents, Department Heads, Leaders and Managers specialising in:

  • Ageing
  • Alzheimer’s
  • Antimicrobials
  • Atherosclerosis
  • Autologous
  • Bacteriotherapy
  • Biofuels
  • Biology
  • Bioreactors
  • Bone Marrow Transplantation
  • Bulk Material
  • Cell Culture
  • Clinical Development
  • Clinical Trial
  • CMO
  • Commercialisation
  • Confocal Microscopy
  • Cytokines
  • Delivery
  • Drug Delivery
  • Ecology
  • Endocrinology
  • Faecal Microbiota
  • Filtration
  • FMT
  • Fusobacteria
  • Gastrointestinal
  • Genomics
  • GMP
  • Gut-Brain Axis
  • Hypertension
  • IBS
  • Immuno-Inflammation
  • In Vitro
  • IND
  • Inflammation
  • Invention
  • Isolation
  • LBPs
  • Lifesciences
  • Live Cell Therapeutics
  • Lyophiliser
  • Medicinal Chemistry
  • Metagenomic
  • Microbiology
  • Microbiota
  • Microganisms
  • Mucosal Immunology
  • NASH
  • Nutraceuticals
  • Nutrition
  • Oncoviruses
  • Pathogen
  • Phages
  • Prebiotics
  • Process Cultivation
  • Production
  • Quality Control
  • Regulatory
  • Sequencing
  • Small Molecule
  • Symbiosys
  • Synthetic Biology
  • Testing
  • Translational Sciences
  • Vaccines
  • Western Blotting
  • ALS
  • Analytical
  • Aseptic
  • Autoimmune
  • Bacteriology
  • Biochemistry
  • Bioinformatics
  • Biomarker
  • Biotechnology
  • Bowel Syndrome
  • Cell Biology
  • CGMP
  • Clinical Study
  • CMC
  • CNS
  • Computational Biology
  • Contract Manufacturing
  • Delivery
  • DNA
  • Dysbiosis
  • Eligobiotics
  • Epidemiology
  • Fermentation
  • Flow Cytometry
  • Freeze Drying
  • Gastroenterology
  • Genome Sequencing
  • GI
  • Gut
  • High Throughput Screening
  • IBD
  • ICH
  • Immuno-Oncology
  • In Vivo
  • Infectious Disease
  • Intellectual Property
  • Investment
  • Laboratory
  • Licensing
  • Live Biotherapeutics
  • Liver Disease
  • Manufacturing
  • Mergers & Acquisition
  • Metatranscriptomics
  • Microbiome
  • Microbiotherapy
  • Molecular Biology
  • Multiple Sclerosis
  • Neurodegenerative
  • Nutrients
  • Obesity
  • Patent
  • PCR
  • Pre-Clinical
  • Probiotics
  • Product Development
  • QA
  • R&D
  • Safety
  • Skin
  • SOP
  • Synbiotics
  • Technology Transfer
  • Tissue Culture
  • Ulcerative Colitis
  • Viruses
  • Yeast
Key Practical Learning Points of the Summit

Emerging tech and developments to bring to the market efficient and safe microbiome products
Regulatory implications of probiotics, LBPs, FMTs and emerging microbiome-based medicines
Critical considerations to design clinical trials for microbiome products
Identifying early investment opportunities
Commercialisation of microbiome-based diagnostics, therapies and services
CMC, QA/QC technical perspectives for microbiome
GMP manufacturing and scaleup considerations applicable for microbiome
Building efficient launch and IP management strategies
Speakers
Dr. Colette Shortt, UK

Global Regulatory Director

J&J

Dr. Erik Spek, US

Vice President – Head of Legal Affairs & IP

Vedanta Biosciences, Inc.

Dr. Magali Cordaillat-Simmons, FR

Scientific & Regulatory Affairs Director

Pharmabiotic Research Institute (PRI)

Dr. Rana Samadfam, CA

Director, In Vivo Pharmacology

Charles River

Dr. Adrien Nivoliez, FR

Chief Executive Officer

Biose Industrie

Dr. Mark FitzGerald, US

Partner; Intellectual Property Counseling & Transactions

Nixon Peabody LLP

Dr. Christian Roghi, UK

Chief Business Officer

EnteroBiotix

Dr. Manfred Ruthsatz, CH

Global Head Regulatory Advocacy

Nestlé Health Science

Dr. Sebastien Guery, DE

Human Microbiome Venture Leader

Dupont / Danisco Deutschland GmbH

Dr. Olaf Larsen, NL

Senior Manager Science & Assistant Professor

Yakult Nederland B.V. & Athena Institute, VU University Amsterdam

Saravanan Thangaraj, US

Industry Analyst, Transformational Health

Frost & Sullivan

Dr. Frédérique Vieville, FR

CEO - Founder

5QBD-Biotech

Dr. Peter Bak, US

Vice President

Back Bay Life Science Advisors

Dragana Skokovic-Sunjic, CA

Clinical Pharmacist & Author

AEProbio (Alliance for Education on Probiotics)

Dr. Morten L. Isaksen, NO

CEO

Bio-Me

Finn Terje Hegge, NO

CTO & Head of Operations

Genetic Analysis AS

Martha Carlin, US

Chief Executive Officer

The BioCollective

Annual

Events

Sponsors and Partners

Sponsor

Sponsor

Media partner

Media partner

Media partner

Media partner

Media partner

"